Sector ratings Gan & Lee Pharmaceuticals.

Equities

End-of-day quote Shanghai S.E. Other stock markets 2026-06-05			5-day change	1st Jan Change
54.58 ^CNY	+1.62%		+4.40%	-19.82%

May. 15	Sandoz Group AG Confirms European Commission Approval for Biosimilars Bysumlog® (Insulin Lispro) and Dazparda® (Insulin Aspart), Strengthening Position in Diabetes	CI
May. 07	Gan & Lee Pharmaceuticals Gets Nod to Market Dazparda in Europe	MT

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Financial revisions	Global Valuation	Visibility	Consensus
GAN & LEE PHARMACEUTICALS.	4.8B		-			-
REGENERON PHARMACEUTICALS, INC.	64.65B		BBB
UCB	57.37B		AA
SAMSUNG BIOLOGICS CO.,LTD.	39.87B		BBB
CSL LIMITED	33.6B		A
BIOGEN INC.	28.84B		AA
INCYTE CORPORATION	20.45B		AA
MODERNA, INC.	18.82B	-	BBB	-		-
INNOVENT BIOLOGICS, INC.	16.99B		AAA
SWEDISH ORPHAN BIOVITRUM AB	16.35B		AA
BRIDGEBIO PHARMA, INC.	13.24B	-	BB	-		-
AXSOME THERAPEUTICS, INC.	11.96B	-	BBB	-		-
ALTEOGEN INC.	11.44B		CCC
BIOMARIN PHARMACEUTICAL INC.	10.97B		BBB			-
KRYSTAL BIOTECH, INC.	8.87B	-	B	-		-
GRIFOLS, S.A.	6.41B		BB
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	6.27B	-	BB	-		-	-
HEBEI CHANGSHAN BIOCHEMICAL PHARMACEUTICAL CO., LTD.	5.09B	-	B	-	-	-	-	-
SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD	5.04B	-	-	-		-	-
SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.	5.02B	-	A	-		-	-
Average	19.3B		A
Weighted average by Cap.			A